BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Apr 30, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) Director & 10% Owner Jack Bendheim Sells Shares
What Happened
Jack Bendheim, a director, officer and reported 10% owner of Phibro Animal Health Corp (PAHC), sold a total of 21,120 shares in open‑market transactions between April 28 and April 30, 2026, for aggregate proceeds of approximately $1,137,594. Individual reported trades:
- 4/28/2026: 1,652 sh @ $55.10 = $91,019
- 4/28/2026: 4,591 sh @ $56.06 = $257,375
- 4/28/2026: 797 sh @ $56.69 = $45,182
- 4/29/2026: 4,002 sh @ $52.70 = $210,907
- 4/29/2026: 3,038 sh @ $53.21 = $161,645
- 4/30/2026: 5,805 sh @ $52.65 = $305,618
- 4/30/2026: 1,235 sh @ $53.32 = $65,848
These were sales (S) — not purchases — which are often routine but provide less direct evidence of bullish conviction than buys.
Key Details
- Dates: April 28–30, 2026. Report filed April 30, 2026 (appears timely).
- Total sold: 21,120 shares for ~ $1.14 million.
- Price detail: reported as weighted averages per trade; underlying transaction prices ranged roughly from $52.00 to $56.875 (per filing footnotes).
- Ownership after transaction: not specified in the summary data provided.
- Notable footnotes:
- Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by BFI Co., LLC on Dec 11, 2025 (F1).
- Some reported securities are directly held by BFI; Mr. Bendheim exercises voting/dispositive power over BFI and may be deemed to share power over those securities (F3). Other reported securities are directly held by Jack Bendheim (F10).
- Several prices are reported as weighted averages and were executed in multiple transactions; the filer offers to provide full per‑price breakdown on request (F2, F4–F9).
Context
Because many of the sales were effected under a pre‑arranged Rule 10b5‑1 plan and some shares were held/managed through BFI Co., LLC, these transactions can reflect pre-planned, routine dispositions by a principal rather than an immediate judgment about the company’s prospects. For retail investors, purchases are generally more informative than routine sales; these filings are factual records of disposition rather than explanations of intent.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-04-28$55.10/sh−1,652$91,019→ 94,228 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-04-28$56.06/sh−4,591$257,375→ 89,637 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-04-28$56.69/sh−797$45,182→ 88,840 total(indirect: See) - Sale
Class A Common Stock
[F1][F6][F3]2026-04-29$52.70/sh−4,002$210,907→ 84,838 total(indirect: See) - Sale
Class A Common Stock
[F1][F7][F3]2026-04-29$53.21/sh−3,038$161,645→ 81,800 total(indirect: See) - Sale
Class A Common Stock
[F1][F8][F3]2026-04-30$52.65/sh−5,805$305,618→ 75,995 total(indirect: See) - Sale
Class A Common Stock
[F1][F9][F3]2026-04-30$53.32/sh−1,235$65,848→ 74,760 total(indirect: See)
Holdings
- 16,840
Class A Common Stock
[F10]
Footnotes (10)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.
- [F10]The reported securities are directly held by Jack Bendheim.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.51 to $55.40. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.51 to $56.50.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.53 to $56.875.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.97.
- [F7]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.775.
- [F8]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.16 to $53.09.
- [F9]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.22 to $53.39.